- Feb. 23, 2021
-- The global chemotherapy induced acral erythema (Hand foot syndrome) treatment market accounted for US$ XX million in 2020 and is estimated to be US$ XX million by 2030 and is anticipated to register a CAGR of XX%. The growth of the healthcare sector at a significant pace and government initiatives to improve healthcare facilities are expected to fuel the chemotherapy induced acral erythema (Hand foot syndrome) treatment market in the forecast period. Key players are investing in research and development of technologically advanced medical examination systems to facilitate chemotherapy induced acral erythema (Hand foot syndrome) treatment market growth.
The report " Global Chemotherapy Induced Acral Erythema (Hand Foot syndrome) Treatment Market, By Product (Analgesics, Anti-Inflammatory& Anti-Edematous Agents, Antihistaminic, NSAIDS, Oral/Topical Glucocorticoids, Pyridoxine(Vitamin B6) and Others (Cold compression, therapy, emollients)), By Severity (Grade1, Grade2, Grade3, Grade4), By End-user (Diagnostics and Research, Pharmacy and Drugstores), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Trends, Analysis, and Forecast till 2030"
- According to the National Center for Biotechnology Information (NCBI), the incidence of developing HFS in patients treated with capecitabine is around 60%.
- According to Central National Investigations Oncology (CNIO) on September 20, 2020 identifies genetic factors associated to hand-foot syndrome in chemotherapy with capecitabine.